The development of cluster of differentiation (CD)-19-targeted chimeric antigen receptor (CAR) T cells for the treatment of pre-B-cell acute lymphoblastic leukemia (B-ALL) is an exciting new advancement in the field of pediatric oncology. Tisagenlecleucel and axicabtagene ciloleucel are the first US FDA-approved CD19
Introduction
Harnessing the intrinsic cytotoxic and immune-supportive ability of T cells against tumor cells is the mainstay of adoptive cellular therapy. As many tumor-associated antigens are not recognized as foreign by the body's immune system, autologous T cells often fail to mount an immunologic response against neoplastic cells. Chimeric antigen receptor (CAR) T cells circumvent this limitation through a major histocompatibility class-independent mechanism, instead using antigen recognition and T-cell receptor complex-like signaling through the engineered CAR. Importantly, this allows for potential targeting of both normal self-antigens, which may be tumor associated, and tumorspecific neoantigens if expressed on the cell surface.
CAR T-cell-targeted immunotherapy has been successful in the treatment of cluster of differentiation (CD)-19-positive leukemias and lymphomas. This includes B-cell acute lymphoblastic leukemia (B-ALL), which is the most common pediatric malignancy. Two US FDAapproved CAR T-cell products target the CD19 antigen, which is expressed on B-cell malignancies. The first is tisagenlecleucel (Kymriah, Novartis), which was approved by the FDA for the treatment of relapsed or refractory (R/R) B-ALL in children and young adults in August 2017 and for R/R diffuse large B-cell lymphoma in adults in May 2018. Axicabtagene ciloleucel or axi-cel (Yescarta, Kite) was also approved for R/R B-cell lymphoma in adults in October 2017 and is being studied for the treatment of pediatric B-ALL. The use of these products includes important considerations in the selection of patients, management of toxicities, measurement of disease response, and indications for additional therapy in patients with a suboptimal response or relapse. The primary aims of this review are to summarize the rationale for and available data on CD19 CAR T cells for B-ALL in pediatrics, to highlight patients who may be good candidates to receive CD19 CAR T cells, and discuss the management of patients after treatment with CAR T cells.
Chimeric Antigen Receptor (CAR) Biology
The CAR is composed of three major domains: antigen recognition, costimulatory signaling, and activation signaling. The CAR structure also includes spacer, linker, and/ or hinge domains, the length and composition of which affect CAR T-cell function and persistence [1] [2] [3] . Extracellular targeting through the antigen-recognition domain is accomplished through a variety of agents, with antibodyderived elements (single chain variable fragment [scFv]) being the most commonly employed method in current CAR constructs. Other novel targeting strategies include the use of nanobodies, D-domains, and Z-domains, among others [4, 5] . As with other immunotherapy strategies, the primary features in selecting an scFv includes targetbinding specificity, binding affinity, and potential immunogenicity. Several scFvs are derived from parent antihuman antibodies raised in nonhuman mammals, including mouse and rabbit. Efforts to humanize the antibody fragments by altering the framework or noncomplementaritydetermining regions may decrease immunogenicity when introduced to patients. Additional considerations when selecting an scFv include evaluation for receptor selfoligomerization, which has been reported to be a feature intrinsic to the scFv, that ultimately may lead to detrimental tonic signaling and early T-cell exhaustion [6] .
Second-and third-generation CAR T cells use one or more costimulatory domains as an integrated signaling region within the chimeric receptor. Second-generation CAR T cells use one costimulatory domain, and third-generation CAR T cells use two or more costimulatory domains [7] . Both of the FDAapproved CAR T-cell products are second-generation CAR T cells; thus far, third-generation CAR T cells have not been shown to have superior efficacy [7] [8] [9] . These are derived from members of the native immunological synapse formed between the T cell and antigen-presenting cells [10] . Costimulatory molecules that have been used in CAR constructs include CD28, 41BB, OX40, and ICOS [11] [12] [13] . Paradigmshifting preclinical research demonstrated that the integration of co-stimulation overcame many of the limitations of firstgeneration CAR T cells, as it improved CAR T-cell proliferation, cytotoxic capabilities, and persistence [11] . Other studies have shown the choice of costimulatory domain may impact T-cell cytokine production and may alter the balance between pro-and anti-inflammatory cytokines [14] . Additionally, different costimulatory domains may protect from T-cell exhaustion, whereas others-through interaction with the scFv or the viral vector-may potentiate the effect of tonic signaling and lead to an early exhausted phenotype [6, 15] . It is important to note that the two FDA-approved CAR T-cell products differ in both costimulatory domain and type of viral vector used for genetic modification. Tisagenlecleucel incorporates a 41BB costimulatory domain and is transduced by lentivirus, whereas axicabtagene ciloleucel employs a CD28 costimulatory domain and is produced by retroviral transduction [16, 17] .
CAR T-Cell Expansion
In addition to specific engineering of the CAR, several studies have also demonstrated the importance of cell culture techniques and influence of supplementary cytokines during CAR T-cell expansion, on the efficacy of the final cell product [8, 18, 19] . T cells are activated by CD3 antibodies, or the combination of CD3/CD28 antibodycoated beads to stimulate proliferation, and are often supplemented with the T-cell proliferation cytokine, interleukin (IL)-2, during ex vivo culture. However, the choice of activation method and use of specific cytokines may shift the composition of the cell product away from memory cells to increased effector cells, which display poorer persistence and an exhausted phenotype. Recent research demonstrated that supplementation with IL-7 and IL-15, rather than IL-2, preserved stem central memory-and central memory-T cells, which improved CAR T-cell function in in vivo models of leukemia [20] . In addition to the specific cytokines used during culture, the length of ex vivo culture time may also affect T-cell differentiation and CAR T persistence. While the FDA-approved CD19 CAR T cells are expanded in culture from 9 to 14 days, decreasing the duration of ex vivo culture may reduce T-cell differentiation and improve potency [8] .
Importantly for the clinician, the timing of T-cell collection in relation to type and cumulative exposure to chemotherapy may also influence the function of CAR T cells when returned to the patient. A recent study demonstrated that T cells exhibited a stepwise decline in in vitro expansion potential with successive cycles of chemotherapy and significantly alter the phenotypic composition by causing selective depletion of the naïve T-cell population [21] . The authors also noted an intrinsic difference in T-cell populations between different tumor types, including standard-risk and high-risk B-ALL, before beginning therapy, suggesting the neoplastic process itself may modulate the host immune system.
ELIANA Trial Results
Tisagenlecleucel (previously known as CTL019) is a CAR T cell targeting CD19 that was initially tested in children and adults at the University of Pennsylvania/Children's Hospital of Philadelphia, USA. Tisagenlecleucel was evaluated in a multicenter phase II study, the ELIANA trial, which included children and young adults with R/R B-ALL [22] . The response rates were high, with an overall response rate (ORR) of 81% (61/75) at 3 months after infusion [22] . The responses were durable, as the median duration of response was not reached. In an updated analysis from the ELIANA trial, the probability of relapse-free survival among responders was 62% at 24 months, and the probability of overall survival (OS) was 66% at 24 months [16] . This was a significant improvement over standard-ofcare therapy for R/R B-ALL.
Patient Selection for Treatment with Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia (B-ALL)
The approval of tisagenlecleucel has provided a new treatment option for patients with R/R B-ALL. The FDA approval is for patients aged ≤ 25 years with B-ALL that is refractory or in second or later relapse [23] . Table 1 lists the eligibility criteria for patients included in the ELIANA trial, where refractory disease was defined as persistent disease following two cycles of upfront chemotherapy or one cycle of relapse chemotherapy [22] . The patients enrolled in the study were highly refractory, and most were thought to have incurable disease. The enrolled patients had received a median of three prior therapies and had a median bone marrow blast percentage of 74%; 61% (46/75) had relapsed after allogeneic stem cell transplant (allo-SCT). The response rate of patients treated on the ELIANA trial with high-risk cytogenetics (hypodiploidy, BCR-ABL1, KMT2A rearrangement, intrachromosomal amplification of chromosome 21, TCF3-HLF, BCR-ABL1-like, CRLF2 rearrangement, and/or TP53 mutation/deletion) were also favorable [24] . Based on the high ORR in these individuals, tisagenlecleucel should be considered for individuals who fit the FDA-approved indications and have similar characteristics to the patients included in the phase II study. One subset of patients with favorable outcomes after treatment with tisagenlecleucel includes those with central nervous system (CNS) involvement, whereas outcomes for patients with other forms of extramedullary disease are unknown. Relapse outcomes are worse for individuals with CNS disease, and patients with a CNS relapse after allo-SCT and/or radiation have few curative options [25] . The treatment of CNS relapse typically includes cranial radiation, which is associated with long-term cognitive toxicity [26] . Rheingold et al. [27] reported the outcomes of 12 patients treated with CTL019 who had highly refractory CNS disease and experienced a relapse after treatment with cranial radiation and/or allo-SCT. The CTL019 transgene was detectable in the cerebrospinal fluid (CSF) of nearly all patients tested, and, at the time of study cutoff, eight patients had an ongoing complete response (CR). It is recommended that patients do not have CNS disease at the time of infusion as this may increase the risk of neurotoxicity [23, 27] . It is also important to note that most patients who received tisagenlecleucel cells for CNS relapse also had bone marrow involvement, and the treatment of isolated CNS relapse warrants further study. Treatment with tisagenlecleucel also led to favorable outcomes in individuals with Down syndrome. Historically, this group of patients had lower survival rates following allo-SCT for relapsed B-ALL [28] . Children and young adults with Down syndrome are also known to experience increased toxicity with chemotherapy and are often excluded from clinical trials investigating novel agents in relapsed B-ALL. These patients were included in the ELIANA trial, and seven individuals with Down syndrome received tisagenlecleucel. The CR rate was high, at 88% (6/7), and patients did not experience increased toxicity [29] . Tisagenlecleucel may also be beneficial in other vulnerable patient groups, such as those with Li-Fraumeni syndrome or Noonan syndrome and patients who are ineligible for allo-SCT because of toxicity from prior therapies, although this warrants further study [30] .
Patients who meet the R/R criteria as defined by the ELI-ANA trial (Table 1) should be considered for treatment with tisagenlecleucel, and other patients with high-risk disease may also benefit from treatment with tisagenlecleucel. For example, patients experiencing a first relapse < 18 months after diagnosis, patients with relapsed infant ALL, and patients with R/R B-ALL with persistent minimal residual disease (MRD) have poor outcomes with standard relapse regimens but were not eligible for the ELIANA trial. Additional studies are needed to determine whether these patients may benefit from treatment with CD19 CAR T cells and whether their outcomes are similar to those of the patients treated during the ELIANA trial.
Adult patients with lymphoma treated with tisagenlecleucel following FDA approval demonstrated similar response rates to those seen in clinical trials, even in patients who would have been ineligible for the phase II trial [31] . Early results from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry of children and young adults with B-ALL treated with tisagenlecleucel following FDA approval have recently been reported and are similar to those seen in the ELIANA clinical trial, with 89% of patients in remission following infusion and 66% leukemia-free survival at 6 months [32] . Additional follow-up of long-term outcomes and dedicated analyses of the cohorts of patients who would not have met clinical trial eligibility criteria warrant further investigation.
One high-risk group of patients includes those with early relapse (< 18 months following diagnosis). Patients with early relapse were eligible for the ELIANA trial only in the setting of refractory disease or second relapse [22] . This group has a very poor prognosis with standard chemotherapy, with a 5-year survival rate of 20%, and earlier treatment with tisagenlecleucel may provide a survival advantage [25] .
Patients who do not meet the age criteria specified in the ELIANA trial may also benefit from treatment with tisagenlecleucel. Infant B-ALL is associated with mixed-lineage leukemia rearrangements and diagnosed before 1 year of age. These individuals have increased rates of relapse and very low survival rates following relapse, with a 2-year OS of 20% [33] . Few patients with infant B-ALL have been treated with tisagenlecleucel because the phase II trial required patients to be aged ≥ 3 years at screening [22] . The collection of T cells by leukapheresis can be technically challenging in younger patients because of their smaller size. However, specific age and weight requirements may vary by institution, and, in our experience, infants can undergo successful leukapheresis for tisagenlecleucel manufacturing. Another option is to consider treatment with allogeneic CD19 CAR T cells if leukapheresis is not feasible, as this was shown to be successful in two infants with B-ALL [34] . UCART19 is an allogeneic CAR T cell that is available through a clinical trial where the eligibility includes children aged < 1 year (NCT02808442).
Treatment with tisagenlecleucel may also be a favorable option in patients with < 5% blasts by morphology but persistent MRD. The presence of MRD is a known risk factor for a worse outcome, especially in patients with positive MRD after 2 cycles of chemotherapy [35, 36] . These patients are typically treated with additional chemotherapy and proceed to allo-SCT if they achieve an MRD-negative state. However, patients who are MRD positive before allo-SCT have very poor outcomes [37] . These patients may experience longstanding remission with tisagenlecleucel while avoiding the toxicity associated with allo-SCT. A clinical trial evaluating patients with positive MRD (> 0.01) after 2 cycles of upfront chemotherapy is currently underway (NCT 03876769), and a cohort has been opened in the ELIANA trial to study patients with early first relapse who are MRD (> 0.01) positive after reinduction therapy (NCT02435849).
Considerations Prior to Infusion of Autologous CAR T Cells
Treatment with autologous CAR T cells requires patients to be well enough to undergo successful collection of peripheral blood T cells and maintain some control of their disease burden during manufacturing. In the ELIANA trial, 15 patients were screened for the study but not enrolled [22] . Eleven of these patients did not meet the clinical eligibility criteria, but two patients died before enrollment and one was not enrolled because they did not have an adequate leukapheresis product for CAR T manufacturing [22] . After leukapheresis is completed, the possibility also exists that the CAR T cells cannot be manufactured. In the ELIANA trial, seven patients enrolled but did not receive tisagenlecleucel because of a manufacturing issue and ten died or had another adverse event preventing treatment [22] . In considering patients for treatment with autologous CD19 CAR T cells, it is important to consider the timing of leukapheresis to reduce the risk of a manufacturing failure. Certain highrisk patient groups may benefit from earlier collection as T cells have demonstrated decreased expansion potential after higher cumulative doses of chemotherapy [20, 38] . At our center, we have considered T-cell collection in high-risk patient groups such as those with induction failure and early relapse. These patients often receive aggressive cytotoxic chemotherapy, and it may be more difficult to obtain a sufficient quantity of T cells for CAR T manufacturing if they do not achieve remission.
Patients who are considered for treatment with tisagenlecleucel need to meet eligibility criteria before leukapheresis, and the collection can only occur at certain approved sites. Furthermore, chemotherapy must be stopped at specific time points, and the patient must have an absolute lymphocyte count ≥ 500 cells/µL or an absolute CD3 count ≥ 150 cells/ µL for adequate collection of T cells [39, 40] . Therefore, it is important to consider CAR T therapy early in patients who may be eligible in order to offer the best chance for adequate T-cell collection.
Following leukapheresis, most patients are treated with bridging chemotherapy during the manufacturing period to prevent acceleration of disease. Several bridging chemotherapy regimens, ranging in intensity, have been reported [39, 41] . In the ELIANA trial, most patients received bridging chemotherapy that was chosen by the investigator. However, ten of the enrolled patients (11%) were unable to receive tisagenlecleucel, the main reasons for which were infection and disease progression [22] . Patients receiving high-intensity bridging chemotherapy regimens are at higher risk of developing serious infection, but adequate disease control is also important [42] . Therefore, the bridging chemotherapy regimen should be individualized and chosen based on prior chemotherapy and toxicities.
Once the T cells near the end of manufacturing, bridging chemotherapy is stopped to allow for recovery [39, 41] . Patients receive lymphodepleting chemotherapy to kill native T cells prior to infusion of tisagenlecleucel. A commonly used regimen combines fludarabine 30 mg/m 2 daily for days 1-4 and cyclophosphamide 500 mg/m 2 daily for days 1 and 2, followed by infusion of cells 2-14 days later [23] . Before the infusion, patients must be reassessed to confirm they are eligible to receive the cells [39, 41] . Specific contraindications to the cell infusion include pregnancy, pulmonary and/or cardiac dysfunction, active graft versus host disease, acceleration of the leukemia burden, or an uncontrolled active infection [23] . Patients who meet the eligibility criteria can be infused in either the inpatient or the outpatient setting and must be closely monitored for the development of toxicities after the infusion.
CAR T Toxicities
Treatment with CAR T cells may result in unique adverse effects. The most well-described acute toxicities are cytokine release syndrome (CRS) and neurotoxicity [23] . CRS is related to cytokine release following the administration of CAR T cells, where the activated T cells engage the immune system resulting in the rapid release of inflammatory cytokines, including IL-6, interferon-γ, and ferritin [22, 43, 44] . The etiology of neurotoxicity after CAR T cells is currently unknown. After the CAR T-cell infusion, patients should be closely monitored for symptoms of CRS for the first 30 days [23] . While the occurrence and severity of neurotoxicity is associated with the presence and severity of CRS, symptoms may also develop separately and can occur as late as 8 weeks after treatment with CAR T cells [16, 23] . Therefore, patients should not operate heavy machinery during this timeframe [23] . The main symptoms of CRS include fever, hypoxia, and hypotension [22, 43, 44] , whereas symptoms of neurotoxicity include headache, encephalopathy, delirium, somnolence, and agitation [22] . Many patients with CRS and neurotoxicity can be managed with supportive care; however, when CRS is severe, treatment with the IL-6 inhibitor tocilizumab and corticosteroids when needed is extremely effective [23] .
Measurement of Response
The response to treatment with CD19 CAR T cells should be assessed 4 weeks following the infusion with a bone marrow aspirate/biopsy for morphology and MRD and a lumbar puncture. If molecular abnormalities were previously identified by polymerase chain reaction, fluorescence in situ hybridization, or karyotyping, these tests should be repeated. Additionally, the utility of immunoglobulin (Ig) next-generation sequencing (NGS) with high sensitivity, up to 10 −6 , for MRD detection has been explored following CAR T-cell therapy for B-ALL. For patients with R/R B-ALL treated with tisagenlecleucel, at 1 month post CAR T-cell infusion, the authors found that patients who were MRD negative by both Ig NGS and flow cytometry had better progressionfree survival and OS than those with detectable MRD [45, 46] . As this assay is now commercially available and FDA approved for MRD assessment for ALL, we propose including this as a routine measure of disease response post CAR T-cell therapy [47] . This test may help to stratify patients with excellent response with low likelihood of disease recurrence versus those at higher risk for early relapse.
After a patient has experienced an MRD-negative CR, they require ongoing follow-up to ensure the remission is sustained. Monthly follow-up for physical exam, complete blood count with differential, and a serum IgG level is recommended, and a bone marrow aspirate for MRD should be considered every 3 months for 6-12 months [39] .
Another important measure of response is confirmation of B-cell aplasia using flow cytometry to identify CD19positive B cells. In the phase II trial, the median persistence of tisagenlecleucel was 168 days, and it has been detected for up to 2.5 years, but no test is commercially available to directly measure the CAR T transgene in patients [16, 22] . Therefore, the absence of CD19-positive cells in the peripheral blood has been used as a surrogate measurement of CAR T-cell persistence and should be followed monthly [39] . In the ELIANA trial, B-cell aplasia occurred in all patients who responded, and 83% experienced B-cell aplasia for at least 6 months [48] . The exact duration of B-cell aplasia needed to maintain an ongoing response is unknown. However, the emergence of CD19-positive B cells within 6 months of CAR T-cell infusion is associated with earlier loss of the CAR transgene compared with patients with B-cell aplasia lasting more than 6 months [49] . Although additional data are needed, current data suggest that patients who have loss of B-cell aplasia/lack of CAR T-cell persistence within 6 months of infusion are at increased risk of relapse [44, 50] . Thus, patients with B-cell recovery prior to 6 months may require additional therapy.
Additional Therapy After Complete Response
The need for additional therapy after achieving a CR with CD19 CAR T cells varies according to the specific CAR T cell. Allo-SCT was previously thought to be the only definitive treatment for patients with refractory or multiple relapsed B-ALL. Most patients treated with CD19 CAR T cells with a CD28 costimulatory domain underwent allo-SCT while in CR to maintain a durable remission [51] . However, several patients remained in remission after treatment with tisagenlecleucel without receiving additional therapy.
In an updated analysis of the ELIANA trial, 65 patients achieved a CR and 29 patients (45%) had ongoing responses and did not receive additional treatment [16] ; 16 patients (25%) received additional therapy while in remission (8/16 underwent allo-SCT) and 19 patients (29%) relapsed without receiving additional therapy [16] . While early response data have been reported for patients receiving tisagenlecleucel following FDA approval, the data are not yet mature enough to evaluate any impact of SCT on outcomes after tisagenlecleucel in the real-world setting [32] . Studies evaluating which patients may benefit from allo-SCT after treatment with CD19 CAR T cells are needed.
Relapse After CAR T Cells
In patients who do not respond or do not achieve a durable remission following treatment with CD19 CAR T cells, there are several mechanisms of relapse. The first is poor persistence of the CAR T cells after treatment. A sign of early loss of CD19 CAR T cells is the presence of hematogones in the bone marrow [30, 39] . Hematogones are benign immature B-cell precursors. Some patients may develop a population of CD19-positive hematogones in the bone marrow while B-cell aplasia is maintained in the peripheral blood. The presence of a large population of hematogones suggests the loss of CAR T-cell persistence. Patients will ultimately develop B-cell recovery and may be at risk for relapse of CD19-positive leukemic disease. In contrast, other patients relapse with CD19-negative disease, which usually occurs in the presence of persistent anti-CD19 CAR T cells. Reported mechanisms leading to antigen loss include the development of mutations or alternate splice variants of CD19, or lineage switching [52] [53] [54] [55] . These patients may continue to have B-cell aplasia, with the emergence of CD19-negative disease identified by flow cytometry. Relapse following treatment with CD19 CAR T cells can be challenging to manage. Such patients should be offered enrollment in clinical trials when available. The current belief is that patients who experience relapse must undergo allo-SCT to obtain a durable remission. Additional treatment to achieve a sufficiently low disease burden to proceed to transplant is usually required. The treatment options vary according to the timing and the type of leukemia present at relapse; potential treatment options are shown in Table 2 .
Treatment Options After Cluster of Differentiation (CD)-19 CAR T-Cell Failure

Reinfusion ± Programmed Death-1 Inhibitor
Patients with early loss of CAR T cells may be managed with reinfusion of CAR T cells, but responses to this can be mixed [50, 51, 56] . The lack of CAR T persistence is believed to be related to T-cell exhaustion, which may be mitigated with checkpoint inhibition using a programmed death (PD)-1 inhibitor. Pembrolizumab and nivolumab are PD-1 inhibitors that have been administered to individuals with early loss of CAR T cells or relapse, and most treated patients experienced re-expansion of CAR T cells [17, 57] . Li et al. [58] reported a response in three of six patients with B-ALL with early B-cell recovery who were treated with a PD-1 inhibitor. Further research is needed to identify which patients will respond to a PD-1 inhibitor and the appropriate timing of the infusion, especially as PD-1 inhibition is associated with a high risk of graft versus host disease in patients who proceed to allo-SCT [59] .
Treatment of CD19-Positive Relapse
Relapse with CD19-positive disease after treatment with tisagenlecleucel can be treated with a different CD19-targeted CAR T cell or other targeted agents against CD19. One such agent is blinatumomab, which is a bispecific T-cell engager that is FDA approved for R/R B-ALL in pediatric patients. Treatment with blinatumomab demonstrated responses in pediatric patients with R/R B-ALL [60, 61] . Blinatumomab contains an antibody against CD19 on the leukemia cells as well as CD3 on T cells, and binding to both targets leads to cytotoxic cell death. To date, few data are available on the use of blinatumomab before or after tisagenlecleucel, as such patients were excluded from the ELIANA trial. Tisagenlecleucel is the only approved CAR T-cell therapy for B-ALL, but other CD19-targeted CAR T cells may be available through clinical trials. These include CD19 CAR T cells with a different costimulatory domain, humanized CD19 CAR T cells, or allogenic CD19 CAR T cells [50, 51, [62] [63] [64] [65] . An important consideration for treatment with a different CAR T cell is that many studies require the presence of disease by morphology, and patients with low levels of disease by MRD may be ineligible.
Treatment of CD19-Negative Relapse
Patients who relapse with CD19-negative disease require treatments targeting an alternative mechanism. One option is to target a different antigen such as CD22, another cell surface marker commonly found on B-ALL cells. Inotuzumab is an anti-CD22 antibody-drug conjugate (ADC) approved for adults with B-ALL. An ADC is a monoclonal antibody against a tumor antigen that is linked to a cytotoxic molecule that leads to cell death when bound and internalized by the target cell. The binding of inotuzumab to CD22 on leukemia cells leads to cell death by activating the cytotoxic antibiotic calicheamicin. Children with R/R B-ALL had a CR rate of 67% after treatment with inotuzumab [66] .
CAR T products that target a different tumor antigen are also an option for patients who relapse with CD19-negative disease. Treatment with CD22-targeted CAR T cells can result in a CR in patients for whom treatment with a CD19targeted CAR T cell had failed [67] . Bispecific CAR T cells with simultaneous targeting of CD19 and CD22 are also under investigation [68] . Additional considerations include the use of combination cytotoxic chemotherapy regimens and other novel or experimental antileukemic agents available through clinical trials.
Conclusion
The FDA approval of tisagenlecleucel and axicabtagene ciloleucel have revolutionized the treatment of individuals with R/R B-cell malignancies. In the case of B-ALL in pediatrics, early referral to a CAR T-cell center is recommended, as the selection and management of patients who receive this therapy involves important considerations. After receiving CAR T cells, patients must be monitored closely for the development of CRS and neurotoxicity, and those who respond require ongoing monitoring and management of B-cell aplasia. R/R disease after CD19 CAR T cells can be difficult to manage, and the optimum treatment has not been identified. Novel agents acting through a variety of new mechanisms continue to be developed, offering potential treatment options to a group of patients with aggressive disease.
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